Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

HOME >> API >> API List 3 >> Octreotide Acetate >> Dosage

DOSAGE
Octreotide Acetate CAS Registry Number 79517-01-4

Withdraw octreotide yearly for approximately 4 wk from patients who received irradiation to assess disease activity. If GH or IGF-1 levels increase and signs and symptoms recur, therapy may be resumed.
Adults

IV / Subcutaneous 50 mcg 3 times daily. Although 100 mcg 3 times daily is the most commonly effective dosage, some patients require up to 500 mcg 3 times daily.
Patients not currently receiving octreotide

Before administering the octreotide long-acting depot formulation , patients not currently receiving octreotide should begin therapy with octreotide immediate-release formulation  given subcutaneously in an initial dosage of 50 mcg 3 times daily. Most patients require 100 to 200 mcg 3 times daily, but some patients require 500 mcg 3 times daily. After maintaining patients on subcutaneous octreotide for at least 2 wk to determine tolerance, patients who are considered responders can be switched to administration of the intragluteal long-acting depot formulation in a dose of 20 mg given IM intragluteally at 4-wk intervals for 3 months; dosage may be adjusted as follows:
GH 2.5 ng/mL or less, IGF-1 normal and clinical symptoms controlled

Maintain octreotide depot dosage at 20 mg every 4 wk.
GH greater than 2.5 ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled

Increase the octreotide depot dosage to 30 mg every 4 wk.
GH 1 ng/mL or less, IGF-1 normal and clinical symptoms controlled

Reduce the octreotide depot dosage to 10 mg every 4 wk.
GH, IGF-1, or symptoms are not adequately controlled at a dose of 30 mg

The dosage may be increased to 40 mg every 4 wk. Higher doses are not recommended.
Dosage adjustments after 2 months

If symptoms are adequately controlled, consider a dose reduction to 10 mg for a trial period. If symptoms recur, dosage should be increased to 20 mg every 4 wk. If symptoms are not adequately controlled, increase the octreotide long-acting depot dose to 30 mg every 4 wk. Patients who achieve good control on a 20 mg dose may have their dose lowered to 10 mg for a trial period. If symptoms recur, increase the dosage to 20 mg every 4 wk. Doses higher than 30 mg are not recommended. Patients with carcinoid tumors and VIPomas who experience periodic exacerbation of symptoms, whether they are being maintained on the immediate-release or long-acting depot formulation, may be given subcutaneous immediate-release injections for a few days at the dosage they were receiving prior to switching to the depot formulation. When symptoms are controlled, the subcutaneous injections may be discontinued.

Information Associated with Product:
DRUG DESCRIPTION DOSAGE >> SIDE EFFECTS PRECAUTIONS INTERACTION CONSUMER INFORMATION
PDF DOWNLOAD	WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order

    Investor Relations    Feedback     Contact Worldwide    Sitemap